Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antipsychotic medication
|
| gptkbp:approvedBy |
1958
|
| gptkbp:ATCCode |
N05AD01
|
| gptkbp:availableOn |
gptkb:tablet
oral solution injectable solution |
| gptkbp:brand |
gptkb:haloperidol
|
| gptkbp:cause |
gptkb:hyperprolactinemia
weight gain restlessness insomnia sudden cardiac death prolonged QT interval |
| gptkbp:contraindication |
gptkb:Parkinson's_disease
CNS depression hypersensitivity to haloperidol |
| gptkbp:developedBy |
gptkb:Janssen_Pharmaceutica
|
| gptkbp:drugClass |
typical antipsychotic
butyrophenone |
| gptkbp:eliminationHalfLife |
14-37 hours (oral)
21 hours (IM) |
| gptkbp:genericName |
gptkb:haloperidol
|
| https://www.w3.org/2000/01/rdf-schema#label |
Haldol
|
| gptkbp:interactsWith |
gptkb:levodopa
gptkb:phenytoin gptkb:rifampin gptkb:CNS_depressants gptkb:carbamazepine lithium quinidine anticholinergic drugs |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
oral
intramuscular injection intravenous injection |
| gptkbp:sideEffect |
constipation
QT prolongation hypotension sedation dry mouth extrapyramidal symptoms neuroleptic malignant syndrome tardive dyskinesia |
| gptkbp:usedFor |
schizophrenia
delirium Tourette syndrome acute psychosis mania nausea and vomiting severe agitation |
| gptkbp:bfsParent |
gptkb:haloperidol
|
| gptkbp:bfsLayer |
6
|